Their potential has been demonstrated by the United States Food and Drug Administration’s (FDA) approval of risdiplam for the treatment of spinal muscular atrophy (SMA), where it promotes the inclusion of exon 7 in SMN2, whose product then compensates for SMN1-inactivating mutations. This evidence concerns the gene SMN1 and spinal muscular atrophy.